Team 3
4/02/97

Serial Number: 08/788,800

CRF Processing Date: 4/02/97
Edited by: _____
Verified by: _____ (STIC staff)

ENTERED

☐ Changed a file from non-ASCII to ASCII

☐ Changed the margins in cases where the sequence text was "wrapped" down to the next line.

☐ Edited a format error in the Current Application Data section, specifically:
_____

☑ Edited the Current Application Data section with the actual current number. The number inputted by the applicant was ☐ the prior application data; or ☑ other _P0987R1_ .

☐ Added the mandatory heading and subheadings for "Current Application Data".

☐ Edited the "Number of Sequences" field. The applicant spelled out a number instead of using an integer.

☐ Changed the spelling of a mandatory field (the headings or subheadings), specifically:
_____

☐ Corrected the SEQ ID NO when obviously incorrect. The sequence numbers that were edited were:
_____

☐ Inserted or corrected a nucleic number at the end of a nucleic line. SEQ ID NO's edited:
_____

☐ Corrected subheading placement. All responses must be on the same line as each subheading. If the applicant placed a response below the subheading, this was moved to its appropriate place.

☐ Inserted colons after headings/subheadings. Headings edited included:
_____

☐ Deleted extra, invalid, headings used by an applicant, specifically:
_____

☐ Deleted: ☐ non-ASCII "garbage" at the beginning/end of files; ☐ secretary initials/filename at end of file; ☐ page numbers throughout text; ☐ other invalid text, such as_____ .

☐ Inserted mandatory headings, specifically: _____

☐ Corrected an obvious error in the response, specifically:
_____

☐ Edited identifiers where upper case is used but lower case is required, or vice versa.

☐ Corrected an error in the Number of Sequences field, specifically:
_____

☐ A "Hard Page Break" code was inserted by the applicant. All occurrences had to be deleted.

☐ Deleted *ending* stop codon in amino acid sequences and adjusted the "(A)Length:" field accordingly (error due to a PatentIn bug). Sequences corrected: _____

☐ Other:
_____
_____
_____

*Examiner: The above corrections must be communicated to the applicant in the first Office Action. DO NOT send a copy of this form.   3/1/95

TEAM 3

PAGE: 1

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/788,800

DATE: 04/02/97
TIME: 16:27:39

INPUT SET: S16681.raw

This Raw Listing contains the General
Information Section and up to the first 5 pages.

SEQUENCE LISTING

1
2
3   (1)   General Information:
4
5   (i) APPLICANT: Bednar, Martin M.
6   Thomas, G. Roger
7   Gross, Cordell E.
8
9   (ii) TITLE OF INVENTION: ANTI-CD18 ANTIBODIES IN STROKE
10
11   (iii) NUMBER OF SEQUENCES: 15
12
13   (iv) CORRESPONDENCE ADDRESS:
14   (A) ADDRESSEE: Genentech, Inc.
15   (B) STREET: 460 Point San Bruno Blvd
16   (C) CITY: South San Francisco
17   (D) STATE: California
18   (E) COUNTRY: USA
19   (F) ZIP: 94080
20
21   (v) COMPUTER READABLE FORM:
22   (A) MEDIUM TYPE: 3.5 inch, 1.44 Mb floppy disk
23   (B) COMPUTER: IBM PC compatible
24   (C) OPERATING SYSTEM: PC-DOS/MS-DOS
25   (D) SOFTWARE: WinPatin (Genentech)
26
27   (vi) CURRENT APPLICATION DATA:
28   (A) APPLICATION NUMBER:
29   (B) FILING DATE: 22-Jan-1997
30   (C) CLASSIFICATION:
31
32 (viii) ATTORNEY/AGENT INFORMATION:
33   (A) NAME: Lee, Wendy M.
34   (B) REGISTRATION NUMBER: 40,378
35   (C) REFERENCE/DOCKET NUMBER: P0987r1
36
37   (ix) TELECOMMUNICATION INFORMATION:
38   (A) TELEPHONE: 415/225-1994
39   (B) TELEFAX: 415/952-9881
40   (C) TELEX: 910/371-7168
41
42 (2) INFORMATION FOR SEQ ID NO:1:
43
44   (i) SEQUENCE CHARACTERISTICS:
45   (A) LENGTH: 98 amino acids
46   (B) TYPE: Amino Acid

PAGE: 2

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/788,800

DATE: 04/02/97
TIME: 16:27:41

INPUT SET: S16681.raw

```
47              (D) TOPOLOGY: Linear
48
49      (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:
50
51      Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
52       1               5                  10                  15
53
54      Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
55                       20                  25                  30
56
57      Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
58                       35                  40                  45
59
60      Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
61                       50                  55                  60
62
63      Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
64                       65                  70                  75
65
66      Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser
67                       80                  85                  90
68
69      Asn Thr Lys Val Asp Lys Arg Val
70                       95          98
71
72      (2) INFORMATION FOR SEQ ID NO:2:
73
74          (i) SEQUENCE CHARACTERISTICS:
75              (A) LENGTH: 98 amino acids
76              (B) TYPE: Amino Acid
77              (D) TOPOLOGY: Linear
78
79          (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:
80
81      Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser
82       1               5                  10                  15
83
84      Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys
85                       20                  25                  30
86
87      Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
88                       35                  40                  45
89
90      Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
91                       50                  55                  60
92
93      Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn
94                       65                  70                  75
95
96      Phe Gly Thr Gln Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser
97                       80                  85                  90
98
99      Asn Thr Lys Val Asp Lys Thr Val
```

PAGE: 3

RAW SEQUENCE LISTING
PATENT APPLICATION US/08/788,800

DATE: 04/02/97
TIME: 16:27:43

INPUT SET: S16681.raw

```
100                        95              98
101
102    (2) INFORMATION FOR SEQ ID NO:3:
103
104        (i) SEQUENCE CHARACTERISTICS:
105            (A) LENGTH: 98 amino acids
106            (B) TYPE: Amino Acid
107            (D) TOPOLOGY: Linear
108
109       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:
110
111    Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser
112     1           5               10                      15
113
114    Arg Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys
115                    20              25                      30
116
117    Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
118                    35              40                      45
119
120    Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
121                    50              55                      60
122
123    Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
124                    65              70                      75
125
126    Leu Gly Thr Gln Thr Tyr Thr Cys Asn Val Asn His Lys Pro Ser
127                    80              85                      90
128
129    Asn Thr Lys Val Asp Lys Arg Val
130                    95              98
131
132    (2) INFORMATION FOR SEQ ID NO:4:
133
134        (i) SEQUENCE CHARACTERISTICS:
135            (A) LENGTH: 98 amino acids
136            (B) TYPE: Amino Acid
137            (D) TOPOLOGY: Linear
138
139       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4:
140
141    Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser
142     1           5               10                      15
143
144    Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys
145                    20              25                      30
146
147    Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
148                    35               40                     45
149
150    Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
151                    50              55                      60
152
```

```
153    Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser
154                    65              70                  75
155
156    Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser
157                    80              85                  90
158
159    Asn Thr Lys Val Asp Lys Arg Val
160                    95          98
161
162    (2) INFORMATION FOR SEQ ID NO:5:
163
164       (i) SEQUENCE CHARACTERISTICS:
165           (A) LENGTH: 107 amino acids
166           (B) TYPE: Amino Acid
167           (D) TOPOLOGY: Linear
168
169       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5:
170
171    Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp
172     1               5               10                  15
173
174    Glu Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn
175                    20              25                  30
176
177    Asn Phe Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn
178                    35              40                  45
179
180    Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp
181                    50              55                  60
182
183    Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser
184                    65              70                  75
185
186    Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val Thr
187                    80              85                  90
188
189    His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn Arg Gly
190                    95              100                 105
191
192    Glu Cys
193        107
194
195    (2) INFORMATION FOR SEQ ID NO:6:
196
197       (i) SEQUENCE CHARACTERISTICS:
198           (A) LENGTH: 105 amino acids
199           (B) TYPE: Amino Acid
200           (D) TOPOLOGY: Linear
201
202       (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6:
203
204    Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser
205     1               5               10                  15
```

```
206
207    Glu Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser
208                     20                  25                  30
209
210    Asp Phe Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser
211                     35                  40                  45
212
213    Ser Pro Val Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln
214                     50                  55                  60
215
216    Ser Asn Asn Lys Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro
217                     65                  70                  75
218
219    Glu Gln Trp Lys Ser His Arg Ser Tyr Ser Cys Gln Val Thr His
220                     80                  85                  90
221
222    Glu Gly Ser Thr Val Glu Lys Thr Val Ala Pro Thr Glu Cys Ser
223                     95                  100                 105
224
225    (2) INFORMATION FOR SEQ ID NO:7:
226
227       (i) SEQUENCE CHARACTERISTICS:
228           (A) LENGTH: 100 amino acids
229           (B) TYPE: Amino Acid
230           (D) TOPOLOGY: Linear
231
232      (xi) SEQUENCE DESCRIPTION: SEQ ID NO:7:
233
234    Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Pro
235     1                   5                  10                  15
236
237    Lys Asn Ser Ser Met Ile Ser Asn Thr Pro Ala Leu Gly Cys Leu
238                     20                  25                  30
239
240    Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser
241                     35                  40                  45
242
243    Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln
244                     50                  55                  60
245
246    Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro His
247                     65                  70                  75
248
249    Gln Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys
250                     80                  85                  90
251
252    Pro Ser Asn Thr Lys Val Asp Lys Arg Val
253                     95                  100
254
255    (2) INFORMATION FOR SEQ ID NO:8:
256
257       (i) SEQUENCE CHARACTERISTICS:
258           (A) LENGTH: 11 amino acids
```

SEQUENCE VERIFICATION REPORT
PATENT APPLICATION *US/08/788,800*

INPUT SET: S16681.raw

Line	Error	Original Text